These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 29911695)

  • 21. Efficacy and Safety of Ibrutinib for Chronic Graft-Versus-Host Disease: A Systematic Review.
    Santosa D; Rizky D; Tandarto K; Kartiyani I; Yunarvika V; Ardini DNE; Setiawan B; Pangarsa EA; Suharti C
    Asian Pac J Cancer Prev; 2023 Dec; 24(12):4025-4033. PubMed ID: 38156834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-Platelet-Derived Growth Factor Receptor Alpha Chain Antibodies Predict for Response to Nilotinib in Steroid-Refractory or -Dependent Chronic Graft-Versus-Host Disease.
    Chen GL; Carpenter PA; Broady R; Gregory TK; Johnston LJ; Storer BE; Beumer JH; Qiu J; Cerda K; Le R; Otani JM; Liu H; Ross MA; Arai S; Flowers MED; McCarthy PL; Miklos DB
    Biol Blood Marrow Transplant; 2018 Feb; 24(2):373-380. PubMed ID: 29051021
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent FDA Approvals in the Treatment of Graft-Versus-Host Disease.
    Martini DJ; Chen YB; DeFilipp Z
    Oncologist; 2022 Aug; 27(8):685-693. PubMed ID: 35443042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Corticosteroid-Free Primary Treatment of Chronic Extensive Graft-versus-Host Disease Incorporating Rituximab.
    Solomon SR; Sizemore CA; Ridgeway M; Zhang X; Smith J; Brown S; Holland HK; Morris LE; Bashey A
    Biol Blood Marrow Transplant; 2015 Sep; 21(9):1576-82. PubMed ID: 25985915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Approaches for the Treatment of Chronic Graft-Versus-Host Disease: Current Status and Future Directions.
    Saidu NEB; Bonini C; Dickinson A; Grce M; Inngjerdingen M; Koehl U; Toubert A; Zeiser R; Galimberti S
    Front Immunol; 2020; 11():578314. PubMed ID: 33162993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Navigating the Complexity of Chronic Graft-vs-Host Disease: Canadian Insights into Real-World Treatment Sequencing.
    Kim D; Taparia M; Robinson E; Mcgee M; Merali T
    Transplant Proc; 2024 Mar; 56(2):409-415. PubMed ID: 38342748
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ruxolitinib for the treatment of steroid refractory pediatric chronic graft-versus-host disease.
    Belina ME; Driscoll TA; Blanchard SK; Cardones AR
    Pediatr Dermatol; 2022 May; 39(3):432-433. PubMed ID: 35234308
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Changes in Immunosuppressive Treatment of Chronic Graft-versus-Host Disease: Comparison of 2 Surveys within Allogeneic Hematopoietic Stem Cell Transplant Centers in Germany, Austria, and Switzerland.
    Wolff D; Hilgendorf I; Wagner-Drouet E; Jedlickova Z; Ayuk F; Zeiser R; Schäfer-Eckart K; Gerbitz A; Stadler M; Klein S; Middeke JM; Lawitschka A; Winkler J; Halter J; Holler E; Kobbe G; Stelljes M; Ditschkowski M; Greinix H
    Biol Blood Marrow Transplant; 2019 Jul; 25(7):1450-1455. PubMed ID: 30876928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ibrutinib for the treatment of chronic graft-vs-host disease in pediatric hematopoietic stem cell transplant patients: A single-center experience.
    Teusink-Cross A; Davies SM; Grimley MS; Chandra S; Flannery A; Dandoy CE; Nelson AS; Marsh RA; Jacoby B; Lane A; Khandelwal P
    Pediatr Transplant; 2020 May; 24(3):e13692. PubMed ID: 32202691
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Healthcare resource utilization and costs among patients with steroid-resistant chronic graft-versus-host disease in the United States: a retrospective claims database analysis.
    Yu J; Lal LS; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
    Curr Med Res Opin; 2021 May; 37(5):755-759. PubMed ID: 33615925
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Chronic graft-versus-host-disease involving the oral mucosa: clinical presentation and treatment].
    Elad S; Levitt M; M Y S
    Refuat Hapeh Vehashinayim (1993); 2008 Nov; 25(4):19-27, 72. PubMed ID: 19263864
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Belumosudil for chronic graft-versus-host disease.
    Taylor B; Cohen J; Tejeda J; Wang TP
    Drugs Today (Barc); 2022 May; 58(5):203-212. PubMed ID: 35535812
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epidemiology and Treatment of Chronic Graft-versus-Host Disease Post-Allogeneic Hematopoietic Cell Transplantation: A US Claims Analysis.
    Bachier CR; Aggarwal SK; Hennegan K; Milgroom A; Francis K; Dehipawala S; Rotta M
    Transplant Cell Ther; 2021 Jun; 27(6):504.e1-504.e6. PubMed ID: 34158154
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis.
    Hui L; Qi L; Guoyu H; Xuliang S; Meiao T
    Expert Rev Hematol; 2020 May; 13(5):565-575. PubMed ID: 32178541
    [No Abstract]   [Full Text] [Related]  

  • 35. Ruxolitinib as Salvage Therapy for Chronic Graft-versus-Host Disease.
    Modi B; Hernandez-Henderson M; Yang D; Klein J; Dadwal S; Kopp E; Huelsman K; Mokhtari S; Ali H; Malki MMA; Spielberger R; Salhotra A; Zain J; Cotliar J; Parker P; Forman S; Nakamura R
    Biol Blood Marrow Transplant; 2019 Feb; 25(2):265-269. PubMed ID: 30201397
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Steroid-Refractory Chronic Graft-Versus-Host Disease: Treatment Options and Nursing Care.
    Cazeau N; Rodriguez S
    Clin J Oncol Nurs; 2023 May; 27(3):259-265. PubMed ID: 37267484
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Three US Food and Drug Administration-approved therapies for chronic GVHD.
    Zeiser R; Lee SJ
    Blood; 2022 Mar; 139(11):1642-1645. PubMed ID: 35081254
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical characteristics of steroid-responsive but dependent chronic graft-versus-host disease: a multicenter retrospective analysis.
    Oyama T; Matsuda K; Honda A; Maki H; Masamoto Y; Murakami D; Toya T; Sakurai M; Kataoka K; Doki N; Kurokawa M
    Int J Hematol; 2023 Feb; 117(2):260-268. PubMed ID: 36251231
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
    Donato V; Kim HT; Stowe P; Reynolds CG; Ritz J; Koreth J; Whangbo JS
    Front Immunol; 2022; 13():954966. PubMed ID: 36189229
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Single-center, Real-world Experience of Chronic GVHD Treatment Using Ibrutinib, Imatinib, and Ruxolitinib and its Treatment Outcomes.
    Linn SM; Novitzky-Basso I; Abduljalil O; Pasic I; Lam W; Law A; Michelis FV; Gerbitz A; Viswabandya A; Lipton J; Kumar R; Mattsson J; Kim DDH
    Hematol Oncol Stem Cell Ther; 2023 Jul; 17(1):60-71. PubMed ID: 37581458
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.